Evaluation of a new commercial IRAIA for bone-specific alkaline phosphatase during treatment with hormone replacement therapy and calcitonin

Clinical Chemistry

Volumn 42, Issue 6 SUPPL., 1996, Pages 973-974

  Overgaard, Kirsten ^a   Alexandersen, Peter ^a   Riis, Bente Fuel ^a   Christiansen, Claus ^a  

^a CENTER FOR CLINICAL AND BASIC RESEARCH   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; CYPROTERONE ACETATE; DESOGESTREL; ESTRADIOL VALERATE; ESTROGEN; GESTAGEN; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; SALCATONIN;

ADULT; AGED; ARTICLE; BONE MINERAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HORMONE SUBSTITUTION; HUMAN; IMMUNORADIOMETRIC ASSAY; INTRANASAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; PHOTON ABSORPTIOMETRY; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PREMENOPAUSE; RANDOMIZED CONTROLLED TRIAL;

ALKALINE PHOSPHATASE; BONE AND BONES; CALCITONIN; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; IMMUNORADIOMETRIC ASSAY; ISOENZYMES; PROGESTINS;

EID: 0030005572     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/42.6.973     Document Type: Article

References (11)

1. Conference report. Consensus Development Conference. Diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 1993;94:646-50.
2. Johnston CC Jr, Hui SL, Witt RM, Appeldorn R, Baker RS, Longcope C. Early menopausal changes in bone mass and sex steroids. J Clin Endocrinol Metab 1985:61:905-11.
3. Riis BJ, Jensen J, Christiansen C. Cyproterone acetate, an alternative gestagen in postmenopausal oestrogen/gestagen therapy. Clin Endocrinol 1987;26:327-34.
4. Riis BJ, Overgaard K, Christiansen C. Biochemical markers of bone turnover to monitor the bone response to postmenopausal hormone replacement therapy. Osteoporos Int 1995;5:276-80.
5. Nielsen NM, von der Recke P, Hansen MA, Overgaard K, Christiansen C. Estimation of the effect of salmon calcitonin in established osteoporosis by biochemical bone markers. Calcif Tissue Int 1994;55:8-11.
6. Garnero P, Delmas PD. Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease. J Clin Endocrinol Metab 1993;77:1046-53.
7. Fishman WH. Alkaline isozymes: recent progress. Clin Biochem 1990;23: 99-104.
8. Parley JR, Hall SL, Ilicas D, Orcut C, Miller BE, Hill CS, Baylink DJ. Quantification of skeletal alkaline phosphatase in osteoporotic serum with wheat germ agglutination precipitation, heat activation, and two-site immunoradiometric assay. Clin Chem 1994;40:1749-56.
9. Panigrahi K; Delmas PD, Singer F, Ryan W, Reiss O, Fisher R, et al. Characteristics of a two-site immunoradiometric assay for human skeletal alkaline phosphatase in serum. Clin Chem 1994;40:822-8.
10. Garnero P, Shin WJ, Gineyts E, Karpf D, Delmas PD. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to Alendronate treatment. J Clin Endocrinol Metab 1994;79:1693-700.
11. Alexandersen P, Hassager C, Riis BJ, The effect of menopause and hormone replacement therapy on bone alkaline phosphatase. Scand J Clin Lab Invest 1995;55:571-6.